Overview

Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find the highest dose combination of tremelimumab and durvalumab [also called MEDI4736]) that can be given before standard of care pre-surgery chemotherapy to patients with HR+, HER2- breast cancer. Researchers also want to learn more about how certain immune cells may change in the body when they are given the drug combination. Researchers also want to find out how patients with HR+, HER2- breast cancer respond to the study drugs before they receive standard chemotherapy treatment.

Phase:

Early Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

AstraZeneca

Treatments:

Antibodies
Antibodies, Monoclonal
Tremelimumab